ATX's Principal Activity is the development of Focal Adhesion Kinase (FAK) inhibiting drug candidates AMP886 and AMP945.
Last (Price) | |
Change | 0.00 (0.00) |
Bid / Ask | - |
Volume | |
Volume (4w avg) | |
Turnover | |
Open | |
Day Range | - |
VWAP | |
Prev Close | |
Last Trade |
1 Week | |
1 Month | |
2022 YTD | |
1 Year | |
vs Sector (1yr) | -46.64% |
vs ASX 200 (1yr) | -50.74% |
Date | Heading | Pages | File Size | Time |
---|---|---|---|---|
Amplia Therapeutics Limited (ATX, formerly Innate Immunotherapeutics Limited) is an Australian pharmaceutical company that is advancing a pipeline of Focal Adhesion Kinase (FAK) inhibitors for cancer and fibrosis. FAK is an increasingly important target in the field of cancer immunology and Amplia has a particular development focus in pancreatic and ovarian cancer. FAK also plays a significant role in a number of chronic diseases, such as idiopathic pulmonary fibrosis (IPF).
No incorporation details available.
Head Office | Melbourne VIC 3000 |
Website | www.ampliatx.com |
Registry | Computershare |
Auditor | Grant Thornton Audit Pty Ltd |
Date Listed | 23 Dec 2013 |
Date | Event |
---|---|
30/05/2022 | Report (Prelim) |
22/07/2022 | Report (Annual) |
23/11/2022 | Report (Interim) |
DPS and Yield calculations use the Pay Date.
See Upcoming Dividends for all ASX companies.
ATX directors must report any change in shareholding to the ASX within 5 business days.
See Director Transactions for all ASX companies.
The current holdings of ATX directors.
A substantial shareholder is a person or entity that owns 5% or more of the voting shares in a company. Shares can be held through multiple entities, so the Substantial Shareholders list differs from the Top 20 Shareholders list.
Shareholding changes less than 1% do not require notification to the market. When all “Last Notice” dates are identical, it suggests that no (or minimal) change has occurred since the most recent Annual Report.
Name | Last Notice | Total Shares | Shares Held (%) |
---|---|---|---|
Blueflag Holdings Pty Ltd | 15/12/2021 | 13,472,500 | 6.95 |
Acorn Capital Limited | 12/11/2021 | 10,071,620 | 6.49 |
Platinum Investment Management Limited | 22/12/2021 | 34,813,002 | 17.96 |
12 month transaction history compiled from ASX announcements.
Date | Name | Bought | Previous % | New % |
---|---|---|---|---|
20-12-21 | Platinum Investment Management Limited | 7,795,002 | 17.45 | 14.97 |
15-12-21 | Blueflag Holdings Pty Ltd | 2,694,500 | 6.96 | 6.95 |
12-11-21 | Blueflag Holdings Pty Ltd | 2,028,000 | 7.02 | 6.96 |
12-11-21 | Acorn Capital Limited | 10,071,620 | -- | 6.49 |
12-11-21 | Platinum Investment Management Limited | 9,849,000 | 16.15 | 17.45 |
12 month transaction history compiled from ASX announcements.
No sell transactions reported by Substantial Shareholders in the past 12 months.
Date | Close | Change | %Chg | Open | High | Low | Volume | Turnover |
---|---|---|---|---|---|---|---|---|
Year | Closing Price | Last Trade |
---|---|---|
2021 | $0.215 | 30 June |
2020 | $0.125 | 30 June |
2019 | $0.097 | 28 June |
All data on this page is supplied by the ASX, Morningstar and Market Index. Read the disclaimer.